Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Labbafinejad Medical Center
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT01044329
First received: January 6, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

January 6, 2010
January 6, 2010
January 2010
August 2010   (final data collection date for primary outcome measure)
Visual acuity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
central macular thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Branch Retinal Vein Occlusion
  • Drug: Bevacizumab
    Intravitreal, 1.25 mg, 3 times, one month apart.
  • Drug: Triamcinolone Acetonide
    Intravitreal, 2 mg, 2 times, two months apart.
  • Active Comparator: Intravitreal bevacizumab
    Intervention: Drug: Bevacizumab
  • Active Comparator: Intravitreal triamcinolone
    Intervention: Drug: Triamcinolone Acetonide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
December 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recent onset (less than 3 months) BRVO

Exclusion Criteria:

  • Any previous intervention
Both
Not Provided
No
Not Provided
Iran, Islamic Republic of
 
NCT01044329
8900
Yes
Alireza ramezani, Ophthamic research center
Shahid Beheshti Medical University
Labbafinejad Medical Center
Not Provided
Shahid Beheshti Medical University
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP